Aquestive Therapeutics (AQST) Retained Earnings (2017 - 2026)

Aquestive Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$455.1 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 17.85% year-over-year to -$455.1 million; the TTM figure through Mar 2026 stood at -$455.1 million (down 17.85% YoY), while the FY2025 annual figure was -$447.0 million, down 23.07% from the prior year.
• Retained Earnings was -$455.1 million for Q1 2026 at Aquestive Therapeutics, down from -$447.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$270.0 million in Q1 2022 to a low of -$455.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$346.3 million across 5 years, with a median of -$331.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings tumbled 34.38% in 2022, then fell 2.53% in 2023.
• A 5-year view of Retained Earnings shows it stood at -$311.2 million in 2022, then dropped by 2.53% to -$319.1 million in 2023, then retreated by 13.83% to -$363.2 million in 2024, then slipped by 23.07% to -$447.0 million in 2025, then fell by 1.8% to -$455.1 million in 2026.
• The last three Retained Earnings figures came in at -$455.1 million (Q1 2026), -$447.0 million (Q4 2025), and -$415.1 million (Q3 2025), per Business Quant data.